1. Home
  2. FTHM vs GDTC Comparison

FTHM vs GDTC Comparison

Compare FTHM & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fathom Holdings Inc.

FTHM

Fathom Holdings Inc.

N/A

Current Price

$0.55

Market Cap

28.8M

Sector

Finance

ML Signal

N/A

Logo CytoMed Therapeutics Limited

GDTC

CytoMed Therapeutics Limited

N/A

Current Price

$0.80

Market Cap

10.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FTHM
GDTC
Founded
2010
2018
Country
United States
Singapore
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.8M
10.4M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
FTHM
GDTC
Price
$0.55
$0.80
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$2.50
N/A
AVG Volume (30 Days)
79.6K
17.9K
Earning Date
05-12-2026
04-24-2026
Dividend Yield
N/A
N/A
EPS Growth
32.71
N/A
EPS
N/A
N/A
Revenue
$420,477,000.00
N/A
Revenue This Year
$11.67
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
25.45
N/A
52 Week Low
$0.40
$0.68
52 Week High
$3.37
$3.68

Technical Indicators

Market Signals
Indicator
FTHM
GDTC
Relative Strength Index (RSI) 29.69 42.46
Support Level $0.48 $0.73
Resistance Level $0.71 $1.08
Average True Range (ATR) 0.04 0.08
MACD -0.01 -0.01
Stochastic Oscillator 0.58 18.30

Price Performance

Historical Comparison
FTHM
GDTC

About FTHM Fathom Holdings Inc.

Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, and Software as a Service (SaaS) offerings to brokerages and agents by leveraging intelliAgent , proprietary cloud-based software. The Company's three operating and reportable segments: Real Estate Brokerage, Mortgage, and Title. The majority of revenue is from Real Estate Brokerage, which provides real estate brokerage services.

About GDTC CytoMed Therapeutics Limited

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

Share on Social Networks: